MBRX (Moleculin Biotech) Ending Cash Position: $10.32 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MBRX Moleculin Biotech Inc MBRX
30 GF Score
Price $2.08
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech Ending Cash Position?

Moleculin Biotech MBRX -3.67% 30 Ending Cash Position is $10.32 Mil as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Moleculin Biotech's Ending Cash Position for the quarter that ended in Mar. 2026 was $10.32 Mil.

Moleculin Biotech's quarterly Ending Cash Position increased from Sep. 2025 ($6.70 Mil) to Dec. 2025 ($8.88 Mil) and increased from Dec. 2025 ($8.88 Mil) to Mar. 2026 ($10.32 Mil).

Moleculin Biotech's annual Ending Cash Position declined from Dec. 2023 ($23.55 Mil) to Dec. 2024 ($4.28 Mil) but then increased from Dec. 2024 ($4.28 Mil) to Dec. 2025 ($8.88 Mil).

Moleculin Biotech Ending Cash Position Related Terms

Moleculin Biotech Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Ending Cash Position Chart

Moleculin Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.90 43.15 23.55 4.28 8.88

Moleculin Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.72 7.56 6.70 8.88 10.32
MBRX
30GF Score
Moleculin Biotech Inc MBRX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Moleculin Biotech's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4.278+4.6
=8.88

Moleculin Biotech's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=8.878+1.439
=10.32

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $10.32 Mil mean?
Moleculin Biotech (MBRX) has a Ending Cash Position of $10.32 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Moleculin Biotech and its competitors.
Is Moleculin Biotech's Ending Cash Position too high?
Moleculin Biotech's current Ending Cash Position is $10.32 Mil. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's Ending Cash Position compare to JAGX and BCDA?
Moleculin Biotech's Ending Cash Position of $10.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current Ending Cash Position is $10.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current Ending Cash Position of $10.32 Mil. The current Ending Cash Position is $10.32 Mil. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Ending Cash Position is $10.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Other Exchanges 0K2H:UK
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score

Get the complete analysis for MBRX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price